Otsuka (OTCMKTS:OTSKY) Reaches New 12-Month High – Still a Buy?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $30.60 and last traded at $30.53, with a volume of 2094 shares trading hands. The stock had previously closed at $30.0950.

Analysts Set New Price Targets

A number of brokerages recently commented on OTSKY. Zacks Research raised Otsuka from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. Morgan Stanley upgraded Otsuka to an “overweight” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. Based on data from MarketBeat, Otsuka has a consensus rating of “Strong Buy”.

Otsuka Stock Up 1.4%

The stock has a 50 day simple moving average of $28.77 and a 200-day simple moving average of $27.22.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.